166 related articles for article (PubMed ID: 37115407)
1. The preclinical study of
Molavipordanjani S; Mousavi T; Khorramimoghaddam A; Talebpour Amiri F; Abedi SM; Hosseinimehr SJ
Ann Nucl Med; 2023 Jul; 37(7):400-409. PubMed ID: 37115407
[TBL] [Abstract][Full Text] [Related]
2. Targeting and imaging of HER2 overexpression tumor with a new peptide-based
Biabani Ardakani J; Akhlaghi M; Nikkholgh B; Hosseinimehr SJ
Bioorg Chem; 2021 Jan; 106():104474. PubMed ID: 33246602
[TBL] [Abstract][Full Text] [Related]
3. Clinical Dose Preparation of [
Menon SR; Mitra A; Chakraborty A; Tawate M; Sahu S; Rakshit S; Gaikwad S; Dhotre G; Damle A; Banerjee S
Cancer Biother Radiopharm; 2022 Jun; 37(5):384-402. PubMed ID: 35575711
[No Abstract] [Full Text] [Related]
4. Initial preclinical evaluation of 68 Ga-DOTA-(Ser) 3 -LTVSPWY peptide as a PET radiotracer for glioblastoma targeting and imaging.
Ranjbar V; Molavipordanjani S; Biabani Ardakani J; Akhlaghi M; Nikkholgh B; Hosseinimehr SJ
Nucl Med Commun; 2022 Aug; 43(8):945-951. PubMed ID: 35754162
[TBL] [Abstract][Full Text] [Related]
5. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
7. An improved
Khodadust F; Ahmadpour S; Aligholikhamseh N; Abedi SM; Hosseinimehr SJ
Eur J Med Chem; 2018 Jan; 144():767-773. PubMed ID: 29291444
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy.
Jiang L; Miao Z; Kimura RH; Liu H; Cochran JR; Culter CS; Bao A; Li P; Cheng Z
Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):613-22. PubMed ID: 21153409
[TBL] [Abstract][Full Text] [Related]
9. Preparation of [
Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A
Nucl Med Biol; 2019; 78-79():31-40. PubMed ID: 31731177
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of new GnRH-I receptor radionuclide therapy with
Zoghi M; Attar Nosrati S; Rogni F; Shirvani G; Johari Daha F
J Labelled Comp Radiopharm; 2019 Jun; 62(7):310-320. PubMed ID: 31033025
[TBL] [Abstract][Full Text] [Related]
11. Targeted Tumor Therapy with Radiolabeled DNA Intercalator: A Possibility? Preclinical Investigations with
Ghosh S; Das T; Suman SK; Kumar C; Sarma HD; Dash A
Biomed Res Int; 2020; 2020():9514357. PubMed ID: 32775454
[TBL] [Abstract][Full Text] [Related]
12. Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging.
Jie LY; Cai LL; Wang LJ; Ying XY; Yu RS; Zhang MM; Du YZ
Int J Nanomedicine; 2012; 7():3981-9. PubMed ID: 22866005
[TBL] [Abstract][Full Text] [Related]
13. Nuclear Localization Signal Enhances the Targeting and Therapeutic Efficacy of a Porphyrin-Based Molecular Cargo: A Systemic In Vitro and Ex Vivo Evaluation.
Kumar N; Sharma AK; Guleria M; Shelar SB; Chakraborty A; Rakshit S; Kolay S; Satpati D; Das T
Mol Pharm; 2024 May; 21(5):2351-2364. PubMed ID: 38477252
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro evaluation of
Zhang J; Wang Z; Liu H; Cai L; Feng Y; Zhou L; Wei H; Xie Y; Chen Y
Hell J Nucl Med; 2019; 22(2):103-110. PubMed ID: 31273351
[TBL] [Abstract][Full Text] [Related]
15. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
16. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
Chakraborty S; Sarma HD; Vimalnath KV; Pillai MR
Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
[TBL] [Abstract][Full Text] [Related]
17.
Pirooznia N; Abdi K; Beiki D; Emami F; Arab SS; Sabzevari O; Soltani-Gooshkhaneh S
Bioorg Chem; 2020 Sep; 102():104100. PubMed ID: 32711088
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Evaluation of
Luna-Gutiérrez M; Cruz-Nova P; Jiménez-Mancilla N; Oros-Pantoja R; Lara-Almazán N; Santos-Cuevas C; Azorín-Vega E; Ocampo-García B; Ferro-Flores G
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569758
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
